SAB Biotherapeutics Target Price

Analysts' average 12-month price target for SAB Biotherapeutics is $11.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.79

Average Target Price

$11.33

199% upside

3 analysts in the last 4 months

High: $13 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-06-24	BarclaysEliana Merle	$13	243% upside
2026-05-20	Jefferies	$11	190.2% upside
2026-05-12	H.C. WainwrightEmily Bodnar	$10	163.9% upside
2026-01-07	UBSMichael Yee	$7	84.7% upside
2025-09-17	Leerink Partners	$7	84.7% upside
2024-06-07	Loop Capital MarketsKumaraguru Raja	$8	111.1% upside
2024-04-02	H.C. WainwrightEdward White	$6	58.3% upside
2022-08-11	Chardan Capital	$3	20.8% downside

SAB Biotherapeutics (SABS) FAQ

As of the most recent data, SABS shows a target price of $11. Scroll down for historical charts and peer comparison views.

If SAB Biotherapeutics moved to the average analyst target of $11, shares would be roughly 199.0% higher than $3.79. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of SAB Biotherapeutics's earnings trajectory.

Besides this target price page, Stockcircle has SAB Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $11) with ownership activity and broader fundamentals.